Answers are grounded in this paper and cite their sources.
Clozapine has been consistently found to be superior to other antipsychotic medications for the treatment of treatment-resistant schizophrenia, specifically in improving persistent psychotic symptoms. It is also associated with an improved quality of life as well as lower hospitalization rates, reduced suicidality, and premature mortality. Despite its lower risk of extrapyramidal side effects (EPS), clozapine is not considered first-line treatment for schizophrenia due to its array of adverse reactions. Rarely, clozapine may cause eosinophilia. We present a case of a 24-year-old Asian patient with treatment-resistant schizophrenia who developed eosinophilic cryptitis and crypt abscess after initiation of clozapine.
No takes yet. Share an insight, caveat, or question.
Chong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: